Article information
Abstract
In recent years, the therapeutic armamentarium available to dermatologists has been extended thanks to the development of numerous biologic agents. In our field, immunomodulators—although currently only approved for psoriasis—have given rise to new therapeutic possibilities in a number of inflammatory skin diseases. Since these new agents have more specific immunologic mechanisms of action, their efficacy and safety is an improvement on traditional immunosuppressants. Consequently, it is very likely that they will play an important role in dermatology in the next few years. This article, the first part of a review of off-label use of biologic agents in dermatology, describes the anti-tumor necrosis factor-α antibodies infliximab and adalimumab.
Key words:
infliximab
adalimumab
off-label
dermatosis
Resumen
En los últimos años el armamento terapéutico de los dermatólogos se ha incrementado como consecuencia de la introducción de múltiples fármacos biológicos. En Dermatología los inmunomoduladores están aprobados únicamente para la psoriasis. No obstante todos estos medicamentos han abierto nuevas posibilidades de tratamiento para numerosas dermatosis inflamatorias. La eficacia y el perfil de seguridad de estos fármacos puede considerarse mejor al de los inmunosupresores clásicos, dado que actúan sobre mecanismos inmunológicos más específicos, siendo muy probable que en los próximos años estos medicamentos biológicos adquieran un importante papel en el campo de la Dermatología. Este artículo, primera parte de la revisión de usos fuera de indicación de fármacos biológicos en Dermatología, describe los anticuerpos antifactor de necrosis tumoral (TNF): infliximab y adalimumab.
Palabras clave:
infliximab
adalimumab
fuera de indicación
dermatosis
Full text is only aviable in PDF
References
[1.]
J.E. Graves, K. Nunley, M.P. Heffernan.
Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2).
J Am Acad Dermatol, 56 (2007), pp. 55-79
[2.]
M.J. Kerns, J.E. Graves, D.I. Smith, M.P. Heffernan.
Off-label uses of biologic agents in dermatology: a 2006 update.
Semin Cutan Med Surg, 25 (2006), pp. 226-240
[3.]
A. Jacobi, B. Manger, G. Schuler, M. Hertl.
Therapeutic application of TNF-alpha inhibitors infliximab and etanercept in inflammatory skin disorders.
J Dtsch Dermatol Ges, 1 (2003), pp. 259-272
[4.]
J.T. Trent, F.A. Kerdel.
Tumor necrosis factor alpha inhibitors for the treatment of dermatologic diseases.
Dermatol Nurs, 17 (2005), pp. 97-107
[5.]
J.D. Williams, C.E. Griffiths.
Cytokine blocking agents in dermatology.
Clin Exp Dermatol, 27 (2002), pp. 585-590
[6.]
N. Scheinfeld.
The medical uses and side effects of etanercept with a focus on cutaneous disease.
J Drugs Dermatol, 3 (2004), pp. 653-659
[7.]
A.F. Alexis, B.E. Strober.
Off-label dermatologic uses of anti-TNF-a therapies.
J Cutan Med Surg, 9 (2005), pp. 296-302
[8.]
W.P. Arend.
The mode of action of cytokine inhibitors.
J Rheumatol, 65 (2002), pp. 16-21
[9.]
L.H. Calabrese.
Molecular differences in anticytokine therapies.
Clin Exp Rheumatol, 21 (2003), pp. 241-248
[11.]
M.J. Wasserman, D.A. Weber, J.A. Guthrie, V.P. Bykerk, P. Lee, E.C. Keystone.
Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number.
J Rheumatol, 31 (2004), pp. 1912-1917
[12.]
A. Cheifetz, M. Smedley, S. Martin, M. Reiter, G. Leone, L. Mayer, et al.
The incidence and management of infusión reactions to infliximab: a large center experience.
Am J Gastroenterol, 98 (2003), pp. 1315-1324
[13.]
K. Bendtzen, P. Geborek, M. Svenson, L. Larsson, M.C. Kapetanovic, T. Saxne.
Treatment of rheumatoid arthritis (RA) with anti-TNF-alpha antibody (Remicade). Individual monitoring of bioavailability and immunogenicity–secondary publication.
Ugeskr Laeger, 169 (2007), pp. 420-423
[14.]
F. Baert, S. Vermeire, M. Noman, G. Van Assche, G. D’Haens, P. Rutgeerts.
Management of ulcerative colitis and Crohn's disease.
Acta Clin Belg, 59 (2004), pp. 304-314
[15.]
F. Baert, M. Noman, S. Vermeire, G. Van Assche, G. D’ Haens, A. Carbonez, et al.
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
N Engl J Med, 348 (2003), pp. 601-608
[16.]
K. Bendtzen, P. Geborek, M. Svenson, L. Larsson, M.C. Kapetanovic, T. Saxne.
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
Arthritis Rheum, 54 (2006), pp. 3782-3789
[17.]
X. Baraliakos, J. Listing, M. Rudwaleit, J. Brandt, R. Alten, G. Burmester, et al.
Safety and efficacy of readministration of infliximab after long-term continuous therapy and withdrawal in patients with ankylosing spondylitis.
J Rheumatol, 34 (2007), pp. 510-515
[18.]
S. Vermeire, M. Noman, G. Van Assche, F. Baert, K. Van Oteen, N. Esters, et al.
Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study.
Gastroenterology, 125 (2003), pp. 32-39
[19.]
Vermeire S, Noman M, van Assche G, Baert F, D’Haens G, Rutgeerts PJ. The effectiviness of concomitant immunosuppressive therapy to suppress formation of antibodies to infliximab in crohn's disease. Gut. In press 2007.
[20.]
R.J. Farrell, M. Alsahli, Y.T. Jeen, K.R. Falchuk, M.A. Peppercorn, P. Michetti.
Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.
Gastroenterology, 124 (2003), pp. 917-924
[21.]
C.D. Hamilton.
Infectious complications of treatment with biologic agents.
Curr Opin Rheumatol, 16 (2004), pp. 393-398
[22.]
V. Kindler, A.P. Sappino.
The beneficial effects of localized tumor necrosis factor production in BCG infection.
Behring Inst Mitt, 88 (1991), pp. 120-124
[23.]
S.L. Brown, M.H. Greene, S.K. Gershon, E.T. Edwards, M.M. Braun.
Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration.
Arthritis Rheum, 46 (2002), pp. 3151-3158
[24.]
P.J. Enayati, K.A. Papadakis.
Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis.
J Clin Gastroenterol, 39 (2005), pp. 303-306
[25.]
N. Mohan, E.T. Edwards, T.R. Cupps, P.J. Oliverio, G. Sandberg, H. Crayton, et al.
Demyelination occurring during antitumor necrosis factor alpha therapy for inflammatory arthritides.
Arthritis Rheum, 44 (2001), pp. 2862-2869
[26.]
C.W. Thomas Jr., B.G. Weinshenker, W.J. Sandborn.
Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease.
Inflamm Bowel Dis, 10 (2004), pp. 28-31
[27.]
T.H. Tran, D. Milea, N. Cassoux, B. Bodaghi, P. Bourgeois, P. LeHoang.
Optic neuritis associated with infliximab.
J Fr Ophtalmol, 28 (2005), pp. 201-204
[28.]
O. Devergne, D. Emilie, M. Peuchmaur, M.C. Crevon, M.F. D’Agay, P. Galanaud.
Production of cytokines in sarcoid lymph nodes: preferential expression of interleukin-1 beta and interferon-gamma genes.
Hum Pathol, 23 (1992), pp. 317-323
[29.]
V. Kindler, A.P. Sappino, G.E. Grau, P.F. Piguet, P. Vassalli.
The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection.
Cell, 56 (1989), pp. 731-740
[30.]
G. Senaldi, S. Yin, C.L. Shaklee, P.F. Piguet, T.W. Mak, T.R. Ulich.
Corynebacterium parvum-and Mycobacterium Boris bacillus Calmette-Guerin-induced granuloma formation is inhibited in TNF receptor I (TNF-RI) knockout mice and by treatment with soluble TNF-RI.
J Immunol, 157 (1996), pp. 5022-5026
[31.]
T. Hino, H. Nakamura, Y. Shibata, S. Abe, S. Kato, H. Tomoike.
Elevated levels of type II soluble tumor necrosis factor receptors in the bronchoalveolar lavage fluids of patients with sarcoidosis.
Lung, 175 (1997), pp. 187-193
[32.]
J. Muller-Quernheim, S. Pfeifer, D. Mannel, J. Strausz, R. Ferlinz.
Lung-restricted activation of the alveolar macrophage/monocyte system in pulmonary sarcoidosis.
Am Rev Respir Dis, 145 (1992), pp. 187-192
[33.]
M.W. Ziegenhagen, U.K. Benner, G. Zissel, P. Zabel, M. Schlaak, J. Muller-Quernheim.
Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers.
Am J Respir Crit Care Med, 156 (1997), pp. 1586-1592
[34.]
Antoniu SA. Infliximab for the therapy of chronic sarcoidosis, Baughman RP, Drent M, Kavuru M et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Expert Opin Investig Drugs. 2007;16:753-6.
[35.]
R. Almodóvar, M. Izquierdo, P. Zarco, F. Javier Quiros, R. Mazzucchelli, B. Steen.
Pulmonary sarcoidosis in a patient with ankylosing spondylitis treated with infliximab.
Clin Exp Rheumatol, 25 (2007), pp. 99-101
[36.]
Uthman I, Touma Z, Khoury M. Cardiac sarcoidosis responding to monotherapy with infliximab. Clin Rheumatol. In press 2007.
[37.]
B.G. Denys, Y. Bogaerts, K.L. Coenegrachts, A.S. De Vriese.
Steroid-resistant sarcoidosis: is antagonism of TNF-alpha the answer?.
Clin Sci (Lond), 112 (2007), pp. 281-289
[38.]
B. Salama, J.J. Gicquel, P. Lenoble, P.L. Dighiero.
Optic neuropathy in refractory neurosarcoidosis treated with TNF-alpha antagonist.
Can J Ophthalmol, 41 (2006), pp. 766-768
[39.]
K.U. Ulbricht, M. Stoll, J. Bierwirth, T. Witte, R.E. Schmidt.
Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis.
Arthritis Rheum, 48 (2003), pp. 3542-3543
[40.]
M. Sollberger, F. Fluri, T. Baumann, S. Sonnet, M. Tamm, A.J. Steck, et al.
Successful treatment of steroid-refractory neurosarcoidosis with infliximab.
J Neurol, 251 (2004), pp. 760-761
[41.]
J.A. Pettersen, D.W. Zochodne, R.B. Bell, L. Martin, M.D. Hill.
Refractory neurosarcoidosis responding to infliximab.
Neurology, 59 (2002), pp. 1660-1661
[42.]
Y. Menon, E. Cucurull, E. Reisin, L.R. Espinoza.
Interferonalpha-associated sarcoidosis responsive to infliximab therapy.
Am J Med Sci, 328 (2004), pp. 173-175
[43.]
J.D. Carter, J. Valeriano, F.B. Vasey, B. Bognar.
Refractory neurosarcoidosis: a dramatic response to infliximab.
Am J Med, 117 (2004), pp. 277-279
[44.]
C. Badgwell, T. Rosen.
Cutaneous sarcoidosis therapy updated.
J Am Acad Dermatol, 56 (2007), pp. 69-83
[45.]
R.P. Baughman, E.E. Lower.
Infliximab for refractory sarcoidosis.
Sarcoidosis Vasc Diffuse Lung Dis, 18 (2001), pp. 70-74
[46.]
M.P. Heffernan, M.J. Anadkat.
Recalcitrant cutaneous sarcoidosis responding to infliximab.
Arch Dermatol, 141 (2005), pp. 910-911
[47.]
L. Mallbris, A. Ljungberg, M.A. Hedblad, P. Larsson, M. Stahle-Backdahl.
Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy.
J Am Acad Dermatol, 48 (2003), pp. 290-293
[48.]
J.H. Meyerle, A. Shorr.
The use of infliximab in cutaneous sarcoidosis.
J Drugs Dermatol, 2 (2003), pp. 413-414
[49.]
H. Haley, W. Cantrell, K. Smith.
Infliximab therapy for sarcoidosis (lupus pernio).
Br J Dermatol, 150 (2004), pp. 146-149
[50.]
C. Pritchard, K. Nadarajah.
Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients.
Ann Rheum Dis, 63 (2004), pp. 318-320
[51.]
S.D. Roberts, D.S. Wilkes, R.A. Burgett, K.S. Knox.
Refractory sarcoidosis responding to infliximab.
Chest, 124 (2003), pp. 2028-2031
[52.]
N.J. Sweiss, M.J. Welsch, J.J. Curran, M.H. Ellman.
Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis.
Arthritis Rheum, 53 (2005), pp. 788-791
[53.]
A.M. Yee, M.B. Pochapin.
Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy.
Ann Intern Med, 135 (2001), pp. 27-31
[55.]
Cruz BA, Reis DD, Araujo CA. Refractory retinal vasculitis due to sarcoidosis successfully treated with infliximab. Rheumatol Int. In press 2007.
[56.]
S. Saleh, S. Ghodsian, V. Yakimova, J. Henderson, O.P. Sharma.
Effectiveness of infliximab in treating selected patients with sarcoidosis.
Respir Med, 100 (2006), pp. 2053-2059
[57.]
J.D. Doty, J.E. Mazur, M.A. Judson.
Treatment of sarcoidosis with infliximab.
Chest, 127 (2005), pp. 1064-1071
[58.]
G. Kolde, J.M. Muche, P. Schulze, P. Fischer, J. Lichey.
Infliximab: a promising new treatment option for ulcerated necrobiosis lipoidica.
Dermatology, 206 (2003), pp. 180-181
[59.]
M.S. Hertl, I. Haendle, G. Schuler, M. Hertl.
Rapid improvement of recalcitrant disseminated granuloma annulare upon treatment with the tumour necrosis factor-alpha inhibitor, infliximab.
Br J Dermatol, 152 (2005), pp. 552-555
[60.]
L. Fardet, A. Dupuy, D. Kerob, A. Levy, M. Allez, E. Begon, et al.
Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients.
J Am Acad Dermatol, 56 (2007), pp. 624-628
[61.]
N. Usmani, T.H. Clayton, S. Everett, M.D. Goodfield.
Variable response of hidradenitis suppurativa to infliximab in tour patients.
Clin Exp Dermatol, 32 (2007), pp. 204-205
[62.]
T.P. Sullivan, E. Welsh, F.A. Kerdel, A.E. Burdick, R.S. Kirsner.
Infliximab for hidradenitis suppurativa.
Br J Dermatol, 149 (2003), pp. 1046-1049
[63.]
A.M. Thielen, C. Barde, J.H. Saurat.
Long-term infliximab for severe hidradenitis suppurativa.
Br J Dermatol, 155 (2006), pp. 1105-1107
[64.]
Y.L. Rosi, L. Lowe, S. Kang.
Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease.
J Dermatol Treat, 16 (2005), pp. 58-61
[65.]
F. Martínez, P. Nos, S. Benlloch, J. Ponce.
Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab.
Inflamm Bowel Dis, 7 (2001), pp. 323-326
[66.]
B. Lebwohl, A.N. Sapadin.
Infliximab for the treatment of hidradenitis suppurativa.
J Am Acad Dermatol, 49 (2003), pp. S275-S276
[67.]
D.R. Adams, K.B. Gordon, A.G. Devenyi, M.D. Ioffreda.
Severe hidradenitis suppurativa treated with infliximab infusion.
Arch Dermatol, 139 (2003), pp. 1540-1542
[68.]
K.H. Katsanos, D.K. Christodoulou, E.V. Tsianos.
Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn's disease patient.
Am J Gastroenterol, 97 (2002), pp. 2155-2156
[69.]
M. Roussomoustakaki, P. Dimoulios, C. Chatzicostas, H.D. Kritikos, J. Romanos, J.G. Panayiotides, et al.
Hidradenitis suppurativa associated with Crohn's disease and spondyloarthropathy: response to anti-TNF therapy.
J Gastroenterol, 38 (2003), pp. 1000-1004
[70.]
M. Shirakawa, K. Uramoto, F.A. Harada.
Treatment of acne conglobata with infliximab.
J Am Acad Dermatol, 55 (2006), pp. 344-346
[71.]
I. Olivieri, A. Padula, G. Ciancio, C. Salvarani, L. Niccoli, F. Cantini.
Successful treatment of SAPHO syndrome with infliximab: report of two cases.
Ann Rheum Dis, 61 (2002), pp. 375-376
[72.]
A. Deutschmann, C.J. Mache, K. Bodo, D. Zebedin, E. Ring.
Successful treatment of chronic recurrent multifocal osteomyelitis with tumor necrosis factor-alpha blockage.
Pediatrics, 116 (2005), pp. 1231-1233
[73.]
M. Iqbal, M.S. Kolodney.
Acne fulminans with synovitisacnepustulosis-hyperostosis-osteitis (SAPHO) syndrome treated with infliximab.
J Am Acad Dermatol, 52 (2005), pp. S118-S120
[74.]
A. Massara, P.L. Cavazzini, F. Trotta.
In SAPHO syndrome anti-TNF-alpha therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations.
Rheumatology (Oxford), 45 (2006), pp. 730-733
[75.]
Z. Reguiai, F. Grange.
The role of anti-tumor necrosis factoralpha therapy in pyoderma gangrenosum associated with inflammatory Bowel disease.
Am J Clin Dermatol, 8 (2007), pp. 67-77
[76.]
M. Regueiro, J. Valentine, S. Plevy, M.R. Fleisher, G.R. Lichtenstein.
Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease.
Am J Gastroenterol, 98 (2003), pp. 1821-1826
[77.]
T. Ljung, M. Staun, O. Grove, O. Fausa, M.H. Vatn, P.M. Hellstrom.
Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab.
Scand J Gastroenterol, 37 (2002), pp. 1108-1110
[78.]
A. Rispo, R. Scarpa, E. Di Girolamo, A. Cozzolino, G. Lembo, M. Atteno, et al.
Infliximab in the treatment of extraintestinal manifestations of Crohn's disease.
Scand J Rheumatol, 34 (2005), pp. 387-391
[79.]
I. Kaufman, D. Caspi, D. Yeshurun, I. Dotan, M. Yaron, O. Elkayam.
The effect of infliximab on extraintestinal manifestations of Crohn's disease.
Rheumatol Int, 25 (2005), pp. 406-410
[80.]
G. Kouklakis, J. Moschos, G.I. Leontiadis, S. Kadis, A. Mpoumponaris, E. Molyvas, et al.
Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report.
Rom J Gastroenterol, 14 (2005), pp. 401-403
[81.]
A.A. Krag, P. Gjersoe.
Treatment with infliximab of peristomal pyoderma gangrenosum in ulcerative colitis.
Ugeskr Laeger, 167 (2005), pp. 1968-1969
[82.]
V.J. Swale, M. Saha, N. Kapur, A.V. Hoffbrand, M.H. Rustin.
Pyoderma gangrenosum outside the context of inflammatory bowel disease treated successfully with infliximab.
Clin Exp Dermatol, 30 (2005), pp. 134-136
[83.]
I. Uthman, J. El-Sayad, A. Sharara.
Successful treatment of recalcitrant pyoderma gangrenosum with infliximab complicated by tuberculosis despite negative screening tests.
Clin Exp Dermatol, 30 (2005), pp. 294
[84.]
M.R. Kaur, H.M. Lewis.
Severe recalcitrant pyoderma gangrenosum treated with infliximab.
Br J Dermatol, 153 (2005), pp. 689-691
[85.]
M. Singh, S.M. Andrew, J.T. Lear.
Infliximab as a treatment for recalcitrant pyoderma gangrenosum.
Clin Exp Dermatol, 29 (2004), pp. 196-197
[86.]
L. Jenne, B. Sauter, P. Thumann, M. Hertl, G. Schuler.
Successful treatment of therapy-resistant chronic vegetating pyoderma gangrenosum with infliximab (chimeric antitumour necrosis factor antibody).
Br J Dermatol, 150 (2004), pp. 380-382
[87.]
A. López San Román, F. Bermejo, I. Aldanondo, E. Carrera, D. Boixeda, E. Muñoz Zato.
Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab.
Rev Esp Enferm Dig, 96 (2004), pp. 420-422
[88.]
M.S. Sapienza, S. Cohen, A.J. Dimarino.
Treatment of pyoderma gangrenosum with infliximab in Crohn's disease.
Dig Dis Sci, 49I 9 (2004), pp. 1454-1457
[89.]
S. Kugathasan, A. Miranda, J. Nocton, B.A. Drolet, C. Raasch, D.G. Binion.
Dermatologic manifestations of Crohn disease in children: response to infliximab.
J Pediatr Gastroenterol Nutr, 37 (2003), pp. 150-154
[90.]
D. Mimouni, G.J. Anhalt, D.J. Kouba, H.C. Nousari.
Infliximab for peristomal pyoderma gangrenosum.
Br J Dermatol, 148 (2003), pp. 813-816
[91.]
A. Zaccagna, A. Bertone, P. Puiatti, F. Picciotto, T. Sprujevnik, R. Santucci, et al.
Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Hypoderma gangrenosum associated with Crohn's disease.
Eur J Dermatol, 13 (2003), pp. 258-260
[92.]
I.D. Arnott, D. McDonald, A. Williams, S. Ghosh.
Clinical use of infliximab in Crohn's disease: the Edinburgh experience.
Aliment Pharmacol Ther, 15 (2001), pp. 1639-1646
[93.]
L.A. Batres, P. Mamula, R.N. Baldassano.
Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease.
J Pediatr Gastroenterol Nutr, 34 (2002), pp. 558-560
[94.]
N. Botros, L. Pickover, K.M. Das.
Image of the Month. Hypoderma gangrenosum caused by ulcerative colitis.
Gastroenterology, 118 (2000), pp. 654-809
[95.]
F. Grange, F. Djilali-Bouzina, A.M. Weiss, A. Polette, J.C. Guillaume.
Corticosteroid-resistant pyoderma gangrenosum associated with Crohn's disease: rapid cure with infliximab.
Dermatology, 205 (2002), pp. 278-280
[96.]
M. Romero-Gómez, D. Sánchez-Muñoz.
Infliximab induces remission of pyoderma gangrenosum.
Eur J Gastroenterol Hepatol, 14 (2002), pp. 907
[97.]
D.G. Sheldon, L.L. Sawchuk, R.A. Kozarek, R.C. Thirlby.
Twenty cases of peristomal pyoderma gangrenosum: diagnostic implications and management.
Arch Surg, 135 (2000), pp. 564-568
[98.]
M.H. Tan, M. Gordon, O. Lebwohl, J. George, M.G. Lebwohl.
Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody.
Arch Dermatol, 137 (2001), pp. 930-933
[99.]
J.K. Triantafillidis, P. Cheracakis, M. Sklavaina, K. Apostolopoulou.
Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum.
Scand J Gastroenterol, 37 (2002), pp. 863-865
[100.]
F. De la Morena, L. Martín, J.P. Gisbert, J. Fernández Herrera, R. Goiriz.
Refractory and infected pyoderma gangrenosum in a patient with ulcerative colitis: response to infliximab.
Inflamm Bowel Dis, 13 (2007), pp. 509-510
[101.]
D.S. Stichweh, M. Punaro, V. Pascual.
Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome.
Pediatr Dermatol, 22 (2005), pp. 262-265
[102.]
V.G. Hubbard, A.C. Friedmann, P. Goldsmith.
Systemic pyoderma gangrenosum responding to infliximab and adalimumab.
Br J Dermatol, 152 (2005), pp. 1059-1061
[103.]
G. Vanbiervliet, R. Anty, S. Schneider, K. Arab, P. Rampal, X. Hebuterne.
Sweet's syndrome and erythema nodosum associated with Crohn's disease treated by infliximab.
Gastroenterol Clin Biol, 26 (2002), pp. 295-297
[104.]
J.F. Rahier, L. Lion, O. Dewit, M. Lambert.
Regression of Sweet's syndrome associated with Crohn's disease after anti-Tumour Necrosis Factor therapy.
Acta Gastroenterol Belg, 68 (2005), pp. 376-379
[105.]
E.N. Foster, K.K. Nguyen, R.A. Sheikh, T.P. Prindiville.
Crohn's disease associated with Sweet's syndrome and Sjogren's synDerksen RH, van Roon JA. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing antidsDNA antibody level.
Rheumatology (Oxford), 45 (2006), pp. 1317-1319
[106.]
F.G. Matzkies, B. Manger, M. Schmitt-Haendle, T. Nagel, H.G. Kraetsch, J.R. Kalden, et al.
Severe septicaemia in a patient with polychondritis and Sweet's syndrome after initiation of treatment with infliximab.
Ann Rheum Dis, 62 (2003), pp. 81-82
[107.]
C. Voigtlander, M. Luftl, G. Schuler, M. Hertl.
Infliximab (anti-tumor necrosis factor alpha antibody): a novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease).
Arch Dermatol, 137 (2001), pp. 1571-1574
[108.]
C. Bonifati, E. Trento, P. Cordiali Fei, L. Muscardin, A. Amantea, M. Carducci.
Early but not lasting improvement of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease) after infliximab therapy: relationships with variations in cytokine levels in suction blister fluids.
Clin Exp Dermatol, 30 (2005), pp. 662-665
[109.]
A. Jacobi, G. Shuler, M. Hertl.
Rapid control of therapyrefractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab.
Br J Dermatol, 153 (2005), pp. 448-449
[110.]
J. Pardo, P. Mercader, L. Mahiques, J.L. Sánchez-Carazo, V. Oliver, J.M. Fortea.
Infliximab in the management of severe pemphigus vulgaris.
Br J Dermatol, 153 (2005), pp. 222-223
[111.]
M.P. Heffernan, D.D. Bentley.
Successful treatment of mucous membrane pemphigoid with infliximab.
Arch Dermatol, 142 (2006), pp. 1268-1270
[112.]
A.H. Hajeer, J. Worthington, E.J. Davies, M.C. Hillarby, K. Poulton, W.E. Ollier.
TNF microsatellite a2, b3 and d2 alleles are associated with systemic lupus erythematosus.
Tissue Antigens, 49 (1997), pp. 222-227
[113.]
M. al-Janadi, S. al-Balla, A. al-Dalaan, S. Raziuddin.
Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases.
J Clin Immunol, 13 (1993), pp. 58-67
[114.]
M. Aringer, E. Feierl, G. Steiner, G.H. Stummvoll, E. Höfler, C.W. Steiner, et al.
Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death.
Lupus, 11 (2002), pp. 102-108
[115.]
J.B. Klapman, D. Ene-Stroescu, M.A. Becker, S.B. Hanauer.
A lupus-like syndrome associated with infliximab therapy.
Inflamm Bowel Dis, 9 (2003), pp. 176-178
[116.]
A.W. van Rijthoven, J.W. Bijlsma, M. Canninga-van Dijk, R.H. Derksen, J.A. van Roon.
Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing antidsDNA antibody level.
Rheumatology (Oxford), 45 (2006), pp. 1317-1319
[117.]
A.J. Stratigos, C. Antoniou, S. Stamathioudaki, G. Avgerinou, A. Tsega, A.D. Katsambas.
Discoid lupus erythematosus-like eruption induced by infliximab.
Clin Exp Dermatol, 29 (2004), pp. 150-153
[118.]
N. Shakoor, M. Michalska, C.A. Harris, J.A. Block.
Drug-induced systemic lupus erythematosus associated with etanercept therapy.
Lancet, 359 (2002), pp. 579-580
[119.]
S.W. Schneider, S. Staender, B. Schluter, T.A. Luger, G. Bonsmann.
Infliximab-induced lupus erythematosus tumidus in a patient with rheumatoid arthritis.
Arch Dermatol, 142 (2006), pp. 115-116
[120.]
C. Richez, C. Dumoulin, T. Schaeverbeke.
Infliximab induced chilblain lupus in a patient with rheumatoid arthritis.
J Rheumatol, 32 (2005), pp. 760-761
[121.]
C. Pérez-García, J. Maymo, M.P. Lisbona Pérez, M. Almirall Bernabe, J. Carbonell Abello.
Drug-induced systemic lupus erythematosus in ankylosing spondylitis associated with infliximab.
Rheumatology (Oxford), 45 (2006), pp. 114-116
[122.]
A. Pataka, A. Tzouvelekis, D. Bouros.
Infliximab-induced non-specific interstitial pneumonia and lupus-like eruption.
Eur J Intern Med, 17 (2006), pp. 520
[123.]
P. Pallotta, G. Cianchini, M. Ruffelli, P. Puddu.
Infliximabinduced lupus-like reaction in a patient with psoriatic arthritis.
Rheumatology (Oxford, 45 (2006), pp. 116-117
[124.]
I. Nakamura, M. Tanno, S. Katsumata, K. Ito.
A lupus-like butterfly rash following infliximab therapy.
Mod Rheumatol, 15 (2005), pp. 223-224
[125.]
W.A. High, M.E. Muldrow, J.E. Fitzpatrick.
Cutaneous lupus erythematosus induced by infliximab.
J Am Acad Dermatol, 52 (2005), pp. E5
[126.]
O. Elkayam, D. Caspi.
Infliximab induced lupus in patients with rheumatoid arthritis.
Clin Exp Rheumatol, 22 (2004), pp. 502-503
[127.]
J.J. de Langen-Wouterse, A.M. Bijl, A.C. van Grootheest.
Drug-induced systemic lupus erythematosus: reports to The Netherlands Pharmacovigilance Centre Lareb.
Ned Tijdschr Geneeskd, 151 (2007), pp. 367-370
[128.]
M. De Bandt, J. Sibilia, X. Le Loet, S. Prouzeau, B. Fautrel, C. Marcelli, et al.
Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
Arthritis Res Ther, 7 (2005), pp. R545-R551
[129.]
T. Chadha, J.E. Hernández.
Infliximab-related lupus and associated valvulitis: a case report and review of the literature.
Arthritis Rheum, 55 (2006), pp. 163-166
[130.]
M. Benucci, F. Li Gobbi, F. Fossi, M. Manfredi, A. Del Rosso.
Drug-induced lupus after treatment with infliximab in rheumatoid arthritis.
J Clin Rheumatol, 11 (2005), pp. 47-49
[131.]
Y. Ali, S. Shah.
Infliximab-induced systemic lupus erythematosus.
Ann Intern Med, 137 (2002), pp. 625-626
[132.]
A. Hoxha, A. Ruffatti, P. Grypiotis, M. Podswiadek, C. Botsios, U. Fiocco, et al.
Antinuclear, anti-dsDNA and anti-ENA antibodies in patients affected with rheumatoid arthritis or ankylosing spondylitis during treatment with infliximab.
Reumatismo, 58 (2006), pp. 121-126
[133.]
E. García-Planella, E. Domenech, M. Esteve-Comas, I. Bernal, E. Cabre, J. Boix, et al.
Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNFalpha antibodies (infliximab).
Eur J Gastroenterol Hepatol, 15 (2003), pp. 351-354
[134.]
C. Eriksson, S. Engstrand, K.G. Sundqvist, S. Rantapaa-Dahlqvist.
Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.
Ann Rheum Dis, 64 (2005), pp. 403-407
[135.]
L. De Rycke, E. Kruithof, N. Van Damme, I.E. Hoffman, N. Van den Bossche, F. Van den Bosch, et al.
Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.
Arthritis Rheum, 48 (2003), pp. 1015-1023
[136.]
L. De Rycke, D. Baeten, E. Kruithof, F. Van den Bosch, E.M. Veys, F. De Keyser.
Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
Arthritis Rheum, 52 (2005), pp. 2192-2201
[137.]
E. Comby, P. Tanaff, D. Mariotte, V. Costentin-Pignol, C. Marcelli, J.J. Ballet.
Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
J Rheumatol, 33 (2006), pp. 24-30
[138.]
Y. Allanore, J. Sellam, F. Batteux, C. Job Deslandre, B. Weill, A. Kahan.
Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab.
Clin Exp Rheumatol, 22 (2004), pp. 756-758
[139.]
P.J. Charles, R.J. Smeenk, J. De Jong, M. Feldmann, R.N. Maini.
Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebocontrolled trials.
Arthritis Rheum, 43 (2000), pp. 2383-2390
[140.]
M. Aringer, G. Steiner, W.B. Graninger, E. Hofler, C.W. Steiner, J.S. Smolen.
Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus.
Arthritis Rheum, 56 (2007), pp. 274-279
[141.]
S.J. Hayat, S.S. Uppal.
Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus.
Mod Rheumatol, 17 (2007), pp. 174-177
[142.]
M. Principi, A. Di Leo, M. Ingrosso, A. Pisani, S. Marangi, A. Amoruso, et al.
Lupus nephritis improvement after antitumor necrosis factor alpha monoclonal antibody (infliximab) treatment for Crohn's disease: a case report.
Immunopharmacol Immunotoxicol, 26 (2004), pp. 243-248
[143.]
S.J. Hayat, S.S. Uppal, M.R. Narayanan Nampoory, K.V. Johny, R. Gupta, M. Al-Oun.
Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis.
Clin Rheumatol, 26 (2007), pp. 973-975
[144.]
M. Aringer, W.B. Graninger, G. Steiner, J.S. Smolen.
Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
Arthritis Rheum, 50 (2004), pp. 3161-3169
[145.]
B. Heilig, C. Fiehn, M. Brockhaus, H. Gallati, A. Pezzutto, W. Hunstein.
Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematodes, progressive systemic sclerosis, and mixed connective tissue disease.
J Clin Immunol, 13 (1993), pp. 321-328
[146.]
M. Hasegawa, M. Fujimoto, K. Kikuchi, K. Takehara.
Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis.
J Rheumatol, 24 (1997), pp. 663-665
[147.]
H. Sato, A.L. Lagan, C. Alexopoulou, D.A. Vassilakis, T. Ahmad, P. Pantelidis, et al.
The TNF-863A allele strongly associates with anticentromere antibody positivity in scleroderma.
Arthritis Rheum, 50 (2004), pp. 558-564
[148.]
M. Hasegawa, S. Sato, T. Nagaoka, M. Fujimoto, K. Takehara.
Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma.
Dermatology, 207 (2003), pp. 141-147
[149.]
R.T. Alekperov, A.V. Timchenko, E.L. Nasonov.
Tumor necrosis factor alpha in systemic scleroderma.
Klin Med (Mosk), 81 (2003), pp. 4-7
[150.]
V. Young, M. Ho, H. Vosper, J.J. Belch, C.N. Palmer.
Elevated expression of the genes encoding TNF-alpha and thromboxane synthase in leucocytes from patients with systemic sclerosis.
Rheumatology (Oxford), 41 (2002), pp. 869-875
[151.]
K. Yamane, H. Ihn, Y. Asano, M. Jinnin, K. Tamaki.
Antagonistic effects of TNF-alpha on TGF-beta signaling through down-regulation of TGF-beta receptor type II in human dermal fibroblasts.
J Immunol, 171 (2003), pp. 3855-3862
[152.]
M. Hamaguchi, Y. Kawahito, H. Ishino, M. Yoshida, T. Yoshikawa.
A case report of tumor necrosis factor-alpha anti-body-induced thrombocytopenia associated with emerging IgM anticardiolipin antibody in patients with scleroderma overlap/rheumatoid arthritis.
Clin Rheumatol, 26 (2007), pp. 988-990
[153.]
Y. Menon, E. Cucurull, L.R. Espinoza.
Pancytopenia in a patient with scleroderma treated with infliximab.
Rheumatology (Oxford), 42 (2003), pp. 1273-1274
[154.]
L. Christopher-Stine, F. Wigley.
Tumor necrosis factor-alpha antagonists induce lupus-like syndrome in patients with scleroderma overlap/mixed connective tissue disease.
J Rheumatol, 30 (2003), pp. 2725-2727
[155.]
P. Ranganathan.
Infliximab-induced scleredema in a patient with rheumatoid arthritis.
J Clin Rheumatol, 11 (2005), pp. 319-322
[156.]
C.M. Magro, A.N. Crowson, C. Ferri.
Cytomegalovirus-associated cutaneous vasculopathy and scleroderma sans inclusion body change.
Hum Pathol, 38 (2007), pp. 42-49
[157.]
K.M. Antoniou, M. Mamoulaki, K. Malagari, H.D. Kritikos, D. Bouros, N.M. Siafakas, et al.
Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease.
Clin Exp Rheumatol, 25 (2007), pp. 23-28
[158.]
E. Bargagli, M. Galeazzi, F. Bellisai, L. Volterrani, P. Rottoli.
Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension.
Respiration, (2005),
[159.]
P. Efthimiou.
Tumor necrosis factor-alpha in inflammatory myopathies: pathophysiology and therapeutic implications.
Semin Arthritis Rheum, 36 (2006), pp. 168-172
[160.]
J.L. De Bleecker, V.I. Meire, W. Declercq, E.H. Van Aken.
Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies.
Neuromuscul Disord, 9 (1999), pp. 239-246
[161.]
I.E. Lundberg.
The role of cytokines, chemokines, and adhesion molecules in the pathogenesis of idiopathic inflammatory myopathies.
Curr Rheumatol Rep, 2 (2000), pp. 216-224
[162.]
I. Lundberg, A.K. Ulfgren, P. Nyberg, U. Andersson, L. Klareskog.
Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies.
Arthritis Rheum, 40 (1997), pp. 865-874
[163.]
I. Lundberg, J.M. Brengman, A.G. Engel.
Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls.
J Neuroimmunol, 63 (1995), pp. 9-16
[164.]
E. Roddy, P.A. Courtney, A. Morris.
Non-Hodgkin's lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab.
Rheumatology (Oxford), 41 (2002), pp. 1194-1195
[165.]
G.J. Hengstman, F.H. van den Hoogen, P. Barrera, M.G. Netea, A. Pieterse, L.B. van de Putte, et al.
Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosisfactor-alpha: preliminary observations.
Eur Neurol, 50 (2003), pp. 10-15
[166.]
G.J. Hengstman, F.H. van den Hoogen, B.G. van Engelen.
Treatment of dermatomyositis and polymyositis with antitumor necrosis factor-alpha: long-term follow-up.
Eur Neurol, 52 (2004), pp. 61-63
[167.]
S. Dold, M.E. Justiniano, J. Márquez, L.R. Espinoza.
Treatment of early and refractory dermatomyositis with infliximab: a report of two cases.
Clin Rheumatol, 26 (2007), pp. 1186-1188
[168.]
C. Korkmaz, G. Temiz, F. Cetinbas, B. Buyukkidan.
Successful treatment of alveolar hypoventilation due to dermatomyositis with anti-tumour necrosis factor-alpha.
Rheumatology (Oxford), 43 (2004), pp. 937-938
[169.]
A. Selva-O’Callaghan, X. Martínez-Costa, R. Solans-Laque, M. Mauri, J.A. Capdevila, M. Vilardell-Tarres.
Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treated with infliximab.
Rheumatology (Oxford), 43 (2004), pp. 1196-1197
[170.]
P. Efthimiou, S. Schwartzman, L.J. Kagen.
Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients.
Ann Rheum Dis, 65 (2006), pp. 1233-1236
[171.]
H. Koski, A. Janin, M.G. Humphreys-Beher, T. Sorsa, M. Malmstrom, Y.T. Konttinen.
Tumor necrosis factor-alpha and receptors for it in labial salivary glands in Sjogren's syndrome.
Clin Exp Rheumatol, 19 (2001), pp. 131-137
[172.]
X. Mariette, P. Ravaud, S. Steinfeld, G. Baron, J. Goetz, E. Hachulla, et al.
Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS).
Arthritis Rheum, 50 (2004), pp. 1270-1276
[173.]
B. Wechsler, R. Sable-Fourtassou, B. Bodaghi, D.L. Huong, N. Cassoux, I. Badelon, et al.
Infliximab in refractory uveitis due to Behçet's disease.
Clin Exp Rheumatol, 22 (2004), pp. S14-S16
[174.]
I. Tugal-Tutkun, A. Mudun, M. Urgancioglu, S. Kamali, E. Kasapoglu, M. Inanc, et al.
Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
Arthritis Rheum, 52 (2005), pp. 2478-2484
[175.]
G. Triolo, M. Vadala, A. Accardo-Palumbo, A. Ferrante, F. Ciccia, E. Giardina, et al.
Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behcet's disease.
Ann Rheum Dis, 61 (2002), pp. 560-561
[176.]
S.P. Travis, M. Czajkowski, D.P. McGovern, R.G. Watson, A.L. Bell.
Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody.
Gut, 49 (2001), pp. 725-728
[177.]
P.P. Sfikakis.
Behcet's disease: a new target for anti-tumour necrosis factor treatment.
Ann Rheum Dis, (2002), pp. 51-53
[178.]
H. Sarwar, H. McGrath Jr, L.R. Espinoza.
Successful treatment of long-standing neuro-Behçet's disease with infliximab.
J Rheumatol, 32 (2005), pp. 181-183
[179.]
C. Ribi, R. Sztajzel, J. Delavelle, C. Chizzolini.
Efficacy of TNF {alpha} blockade in cyclophosphamide resistant neuro-Behcet disease.
J Neurol Neurosurg Psychiatry, 76 (2005), pp. 1733-1735
[180.]
S. Ohno, S. Nakamura, S. Hori, M. Shimakawa, H. Kawashima, M. Mochizuki, et al.
Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis.
J Rheumatol, 31 (2004), pp. 1362-1368
[181.]
S. Nakamura, S. Ohno.
Anti-tumor necrosis factor alpha antibody in the treatment of Behçet's disease.
Int Ophthalmol Clin, 45 (2005), pp. 179-189
[182.]
T. Mussack, N. Landauer, R. Ladurner, U. Schiemann, M. Goetzberger, C. Burchardi, et al.
Successful treatment of cervical esophageal perforation in Behçet's disease with drainage operation and infliximab.
Am J Gastroenterol, 98 (2003), pp. 703-704
[183.]
P.V. Hassard, S.W. Binder, V. Nelson, E.A. Vasiliauskas.
Antitumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report.
Gastroenterology, 120 (2001), pp. 995-999
[184.]
P.H. Goossens, R.J. Verburg, F.C. Breedveld.
Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy.
Ann Rheum Dis, 60 (2001), pp. 637
[185.]
L.P. Robertson, P. Hickling.
Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab.
Rheumatology (Oxford), 40 (2001), pp. 473-474
[186.]
C. Estrach, S. Mpofu, R.J. Moots.
Behçet's syndrome: response to infliximab after failure of etanercept.
Rheumatology (Oxford), 41 (2002), pp. 1213-1214
[187.]
M. Rozenbaum, I. Rosner, E. Portnoy.
Remission of Behçet's syndrome with TNFalpha blocking treatment.
Ann Rheum Dis, 61 (2002), pp. 283-284
[188.]
S. Gulli, C. Arrigo, L. Bocchino, L. Morgante, D. Sangari, I. Castagna, et al.
Remission of Behcet's disease with antitumor necrosis factor monoclonal antibody therapy: a case report.
BMC Musculoskelet Disord, 4 (2003), pp. 19
[189.]
F.T. Saulsbury, J.A. Mann.
Treatment with infliximab for a child with Behçet's disease.
Arthritis Rheum, 49 (2003), pp. 599-600
[190.]
G. Haugeberg, M. Velken, V. Johnsen.
Successful treatment of genital ulcers with infliximab in Behçet's disease.
Ann Rheum Dis, 63 (2004), pp. 744-745
[191.]
M. Connolly, J.S. Armstrong, D.A. Buckley.
Infliximab treatment for severe orogenital ulceration in Behçet's disease.
Br J Dermatol, 153 (2005), pp. 1073-1075
[192.]
A.E. Yucel, H. Kart-Koseoglu, Y.A. Akova, B. Demirhan, S. Boyacioglu.
Failure of infliximab treatment and occurrence of erythema nodosum during therapy in two patients with Behçet's disease.
Rheumatology (Oxford), 43 (2004), pp. 394-396
[193.]
C. Schmaltz, O. Alpdogan, S.J. Muriglan, B.J. Kappel, J.A. Rotolo, E.T. Ricchetti, et al.
Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation.
Blood, 101 (2003), pp. 2440-2445
[194.]
N. Tsukada, T. Kobata, Y. Aizawa, H. Yagita, K. Okumura.
Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation.
Blood, 93 (1999), pp. 2738-2747
[195.]
K.R. Cooke, G.R. Hill, A. Gerbitz, L. Kobzik, T.R. Martin, J.M. Crawford, et al.
Tumor necrosis factor-alpha neutralization reduces lung injury after experimental allogeneic bone marrow transplantation.
Transplantation, 70 (2000), pp. 272-279
[196.]
K. Hattori, T. Hirano, H. Miyajima, N. Yamakawa, M. Tateno, K. Oshimi, et al.
Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies.
Blood, 91 (1998), pp. 4051-4055
[197.]
M.D. Grounds, M. Davies, J. Torrisi, T. Shavlakadze, J. White, S. Hodgetts.
Silencing TNFalpha activity by using remicade or Enbrel blocks inflammation in whole muscle grafts: an in vivo bioassay to assess the efficacy of anti-cytokine drugs in mice.
Cell Tissue Res, 320 (2005), pp. 509-515
[198.]
C. Borsotti, A.R. Franklin, S.X. Lu, T.D. Kim, O.M. Smith, D. Suh, et al.
Absence of donor T cell derived soluble TNF decreases graft-versus-host-disease without impairing graft-versus-tumor activity.
Blood, 110 (2007), pp. 783-786
[199.]
E. Holler, H.J. Kolb, A. Moller, J. Kempeni, S. Liesenfeld, H. Pechumer, et al.
Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation.
Blood, 75 (1990), pp. 1011-1016
[200.]
P. Hervé, E. Racadot, J. Wijdenes, M. Flesch, P. Tiberghien, P. Bordigoni, et al.
Monoclonal anti TNF alpha antibody in the treatment of acute GvHD refractory both to corticosteroids and anti IL-2 R antibody.
Bone Marrow Transplant, (1991), pp. 149
[201.]
V. Barak, F. Levi-Schaffer, B. Nisman, A. Nagler.
Cytokine dysregulation in chronic graft versus host disease.
Leuk Lymphoma, 17 (1995), pp. 169-173
[202.]
K.Y. Chiang, S. Abhyankar, K. Bridges, K. Godder, J.P. Henslee-Downey.
Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease.
Transplantation, 73 (2002), pp. 665-667
[203.]
D.R. Couriel, K. Hicks, S. Giralt, R.E. Champlin.
Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation.
Curr Opin Oncol, 12 (2000), pp. 582-587
[204.]
D.A. Jacobsohn.
Novel therapeutics for the treatment of graft-versus-host disease.
Expert Opin Investig Drugs, 11 (2002), pp. 1271-1280
[205.]
D. Couriel, R. Saliba, K. Hicks, C. Ippoliti, M. de Lima, C. Hosing, et al.
Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.
Blood, 104 (2004), pp. 649-654
[206.]
D.H.K. Couriel, C. Ipolotti.
Infliximab for the treatment of graft-versus-host disease in allogenic transplant recipients: an update.
Blood, 46 (2000), pp. 400a
[207.]
W.A. Ross.
Treatment of gastrointestinal acute graft-versushost disease.
Curr Treat Options Gastroenterol, 8 (2005), pp. 249-258
[208.]
F. Patriarca, A. Sperotto, D. Damiani, G. Morreale, F. Bonifazi, A. Olivieri, et al.
Infliximab treatment for steroid-refractory acute graft-versus-host disease.
Haematologica, 89 (2004), pp. 1352-1359
[209.]
G. Kobbe, P. Schneider, U. Rohr, R. Fenk, F. Neumann, M. Aivado, et al.
Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody.
Bone Marrow Transplant, 28 (2001), pp. 47-49
[210.]
T. Yamane, R. Yamamura, Y. Aoyama, H. Nakamae, T. Hasegawa, C. Sakamoto, et al.
Infliximab for the treatment of severe steroid refractory acute graft-versus-host disease in three patients after allogeneic hematopoietic transplantation.
Leuk Lymphoma, 44 (2003), pp. 2095-2097
[211.]
M.H.R. Magalhaes-Silverman, A. Becker, R. Gringrich.
Treatment of steroid refractory acute graft versus host disease with infliximab.
Blood, 98 (2001), pp. 5208a
[212.]
V. Rodríguez, P.M. Anderson, B.A. Trotz, C.A. Arndt, J.A. Allen, S.P. Khan.
Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut.
Pediatr Blood Cancer, (2005),
[213.]
J.H. Antin, A.R. Chen, D.R. Couriel, V.T. Ho, R.A. Nash, D. Weisdorf.
Novel approaches to the therapy of steroidresistant acute graft-versus-host disease.
Biol Blood Marrow Transplant, 10 (2004), pp. 655-668
[214.]
F.M. Marty, S.J. Lee, M.M. Fahey, E.P. Alyea, R.J. Soiffer, J.H. Antin, et al.
Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study.
Blood, 102 (2003), pp. 2768-2776
[215.]
W.C. Liao, D.F. Mutasim.
Infliximab for the treatment of adult-onset pityriasis rubra pilaris.
Arch Dermatol, 141 (2005), pp. 423-425
[216.]
S. Manoharan, S. White, K. Gumparthy.
Successful treatment of type I adult-onset pityriasis rubra pilaris with infliximab.
Australas J Dermatol, 47 (2006), pp. 124-129
[217.]
R. Lu, S.J. George, S. Hsu.
Pityriasis rubra pilaris: failure of combination treatment with acitretin and infliximab.
Dermatol Online J, 12 (2006), pp. 18
[218.]
M. Fischer, E. Fiedler, W.C. Marsch, J. Wohlrab.
Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis.
Br J Dermatol, 146 (2002), pp. 707-709
[219.]
S. Al-Shouli, N. Abouchala, M.J. Bogusz, M. Al Tufail, K. Thestrup-Pedersen.
Toxic epidermal necrolysis associated with high intake of sildenafil and its response to infliximab.
Acta Derm Venereol, 85 (2005), pp. 534-535
[220.]
R.E. Hunger, T. Hunziker, U. Buettiker, L.R. Braathen, N. Yawalkar.
Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment.
J Allergy Clin Immunol, 116 (2005), pp. 923-924
[221.]
F. Meiss, P. Helmbold, N. Meykadeh, G. Gaber, W. Marsch, M. Fischer.
Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-alpha antibody infliximab: report of three cases.
J Eur Acad Dermatol Venereol, 21 (2007), pp. 717-719
[222.]
A. Booth, L. Harper, T. Hammad, P. Bacon, M. Griffith, J. Levy, et al.
Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis.
J Am Soc Nephrol, 15 (2004), pp. 717-721
[223.]
S.R. Sangle, G.R. Hughes, D.P. D’Cruz.
Infliximab in patients with systemic vasculitis that is difficult to treat: poor outcome and significant adverse effects.
Ann Rheum Dis, 66 (2007), pp. 564-565
[224.]
A.D. Booth, D.R. Jayne, R.K. Kharbanda, C.M. McEniery, I.S. Mackenzie, J. Brown, et al.
Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation.
Circulation, 109 (2004), pp. 1718-1723
[225.]
P. Bartolucci, J. Ramanoelina, P. Cohen, A. Mahr, P. Godmer, C. Le Hello, et al.
Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients.
Rheumatology (Oxford), 41 (2002), pp. 1126-1132
[226.]
P. Lamprecht, O. Arbach, J. Voswinkel, T. Lilienthal, B. Nölle, M. Heller, et al.
Induction of remission with infliximab in therapy-refractory Wegener's granulomatosis — Follow-up of six patients.
Dtsch Med Wochenschr, 127 (2002), pp. 1876-1880
[227.]
R. Farah, S. Lisitsin, M. Shay.
Bacterial meningitis associated with infliximab.
Pharm World Sci, 28 (2006), pp. 123-125
[228.]
A.D. Booth, H.J. Jefferson, W. Ayliffe, P.A. Andrews, D.R. Jayne.
Safety and efficacy of TNFalpha blockade in relapsing vasculitis.
Ann Rheum Dis, 61 (2002), pp. 559
[229.]
J. Hermann, P. Reittner, M. Scarpatetti, W. Graninger.
Successful treatment of meningeal involvement in Wegener's granulomatosis with infliximab.
Ann Rheum Dis, 65 (2006), pp. 691-692
[230.]
P. Svozilkova, E. Rihova, M. Brichova, P. Diblik, P. Kuthan, T. Poch.
Infliximab in the treatment of Wegener's granulomatosis: case report.
Cesk Slov Oftalmol, 62 (2006), pp. 280-286
[231.]
Y. El-Shabrawi, J. Hermann.
Anti-TNF alpha therapy in chronic necrotizing scleritis resistant to standard immunomodulatory therapy in a patient with Wegener's granulomatosis.
Eye, 19 (2005), pp. 1017-1018
[232.]
J. Kleinert, M. Lorenz, W. Kostler, W. Horl, G. Sunder-Plassmann, A. Soleiman.
Refractory Wegener's granulomatosis responds to tumor necrosis factor blockade.
Wien Klin Wochenschr, 116 (2004), pp. 334-338
[233.]
N.M. Wilkinson, E. Erendzhinova, A. Zeft, D.A. Cabral.
Infliximab as rescue therapy in three cases of paediatric Wegener's granulomatosis.
Rheumatology (Oxford), 45 (2006), pp. 1047-1048
[234.]
H. Ozdogu, C. Boga, F. Bolat, M.E. Ertorer.
Wegener's granulomatosis with a possible thyroidal involvement.
J Natl Med Assoc, 98 (2006), pp. 956-958
[235.]
J.H. Stone, M.L. Uhlfelder, D.B. Hellmann, S. Crook, N.M. Bedocs, G.S. Hoffman.
Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety.
Arthritis Rheum, 44 (2001), pp. 1149-1154
[236.]
E.C. Keystone.
The utility of tumour necrosis factor blockade in orphan diseases.
Ann Rheum Dis, 63 (2004), pp. 79-83
[237.]
S.V. Torrente, R.C. Guerri, C. Pérez-García, P. Benito, J. Carbonell.
Amaurosis in patients with giant cell arteritis: treatment with anti-tumour necrosis factor-alpha.
Intern Med J, 37 (2007), pp. 280-281
[238.]
I. Uthman, N. Kanj, S. Atweh.
Infliximab as monotherapy in giant cell arteritis.
Clin Rheumatol, 25 (2006), pp. 109-110
[239.]
G.S. Hoffman, M.C. Cid, K.E. Rendt-Zagar, P.A. Merkel, C.M. Weyand, J.H. Stone, et al.
Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial.
Ann Intern Med, 146 (2007), pp. 621-630
[240.]
Brik R, Gepstein V, Shahar E, Goldsher D, Berkovitz D. Tumor necrosis factor blockade in the management of children with orphan diseases. Clin Rheumatol. In press 2007.
[241.]
S.W. de Kort, M.A. van Rossum, R. ten Cate.
Infliximab in a child with therapy-resistant systemic vasculitis.
Clin Rheumatol, 25 (2006), pp. 769-771
[242.]
K. Wu, D. Throssell.
A new treatment for polyarteritis nodosa.
Nephrol Dial Transplant, 21 (2006), pp. 1710-1712
[243.]
J. Al-Bishri, N. le Riche, J.E. Pope.
Refractory polyarteritis nodosa successfully treated with infliximab.
J Rheumatol, 32 (2005), pp. 1371-1373
[244.]
O. Arbach, W.L. Gross, A. Gause.
Treatment of refractory Churg-Strauss-Syndrome (CSS) by TNF-alpha blockade.
Immunobiology, 206 (2002), pp. 496-501
[245.]
R. Mang, T. Ruzicka, H. Stege.
Therapy for severe necrotizing vasculitis with infliximab.
J Am Acad Dermatol, 51 (2004), pp. 321-322
[246.]
I.W. Uthman, Z. Touma, J. Sayyad, S. Salman.
Response of deep cutaneous vasculitis to infliximab.
J Am Acad Dermatol, 53 (2005), pp. 353-354
[247.]
D.J. Armstrong, M.T. McCarron, G.D. Wright.
Successful treatment of rheumatoid vasculitis-associated foot-drop with infliximab.
J Rheumatol, 32 (2005), pp. 759
[248.]
L.P.D. Thirion, O. Mejjad, P. Courville, X. Le Loet, P. Joly.
Cutaneous vasculitis with necrotic ulcers in rheumatoid arthritis: treatment with anti-TNFalpha.
Ann Dermatol Venereol, 133 (2006), pp. 453-455
[249.]
A.E. van der Bijl, C.F. Allaart, J. Van Vugt, S. Van Duinen, F.C. Breedveld.
Rheumatoid vasculitis treated with infliximab.
J Rheumatol, 32 (2005), pp. 1607-1609
[250.]
F. Tanaka, A. Kawakami, N. Iwanaga, M. Tamai, Y. Izumi, K. Aratake, et al.
Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate.
Intern Med, 45 (2006), pp. 313-316
[251.]
A. Della Rossa, A. Tavoni, G. Merlini, C. Baldini, M. Sebastiani, M. Lombardi, et al.
Two Takayasu arteritis patients successfully treated with infliximab: a potential diseasemodifying agent?.
Rheumatology (Oxford), 44 (2005), pp. 1074-1075
[252.]
M. Jolly, J.J. Curran.
Infliximab-responsive uveitis and vasculitis in a patient with Takayasu arteritis.
J Clin Rheumatol, 11 (2005), pp. 213-215
[253.]
G.S. Hoffman, P.A. Merkel, R.D. Brasington, D.J. Lenschow, P. Liang.
Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis.
Arthritis Rheum, 50 (2004), pp. 2296-2304
[254.]
M.G.C.I.T. Bonilla Hernán, E. De Miguel Mendieta, E. Martín Mola.
Tratamiento con infliximab (anti-TNF alpha) en pacientes con enfermedad de Still del adulto. Experiencia de dos casos.
An Med Interna, 21 (2004), pp. 23-26
[255.]
M.J. O’Connor, F.T. Saulsbury.
Incomplete and atypical Kawasaki disease in a young infant: severe, recalcitrant disease responsive to infliximab.
Clin Pediatr (Phila), 46 (2007), pp. 345-348
[256.]
E.V. Stenbog, B. Windelborg, A. Horlyck, T. Herlin.
The effect of TNFalpha blockade in complicated, refractory Kawasaki disease.
Scand J Rheumatol, 35 (2006), pp. 318-321
[257.]
F. Zulian, G. Zanon, G. Martini, G. Mescoli, O. Milanesi.
Efficacy of infliximab in long-lasting refractory Kawasaki disease.
Clin Exp Rheumatol, 24 (2006), pp. 453
[258.]
T. Saji, Y. Kemmotsu.
Infliximab for Kawasaki syndrome.
J Pediatr, 149 (2006), pp. 426
[259.]
J.C. Burns, W.H. Mason, S.B. Hauger, H. Janai, J.F. Bastian, J.D. Wohrley, et al.
Infliximab treatment for refractory Kawasaki syndrome.
J Pediatr, 146 (2005), pp. 662-667
[260.]
S. Daysal, G. Akcil, B. Goker, S. Haznedaroglu, N. Ercan, M.A. Ozturk.
Infliximab therapy in a patient with familial Mediterranean fever and chronic hip arthritis.
Artritis Rheum, 53 (2005), pp. 146-147
[261.]
S. Metyas, D.G. Arkfeld, D.M. Forrester, G.R. Ehresmann.
Infliximab treatment of familial mediterranean fever and its effect on secondary AA amyloidosis.
J Clin Rheumatol, 10 (2004), pp. 134-137
[262.]
S. Ozgocmen, L. Ozcakar, O. Ardicoglu, E. Kocakoc, A. Kaya, A. Kiris.
Familial mediterranean fever responds well to infliximab: single case experience.
Clin Rheumatol, 25 (2006), pp. 83-87
[263.]
S. Yuksel, F. Yalcinkaya, B. Acar, Z.B. Ozcakar, B. Ozturk, M. Ekim.
Clinical improvement with infliximab in a child with amyloidosis secondary to familial mediterranean fever.
Rheumatology (Oxford), 45 (2006), pp. 1307-1308
[264.]
N.K. Bender, C.E. Heilig, B. Droll, J. Wohlgemuth, F.P. Armbruster, B. Heilig.
Immunogenicity, efficacy and adverse events of adalimumab in RA patients.
Rheumatol Int, 27 (2007), pp. 269-274
[265.]
L.B. van de Putte, C. Atkins, M. Malaise, J. Sany, A.S. Russell, P.L. van Riel, et al.
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed.
Ann Rheum Dis, 63 (2004), pp. 508-516
[266.]
M.E. Weinblatt, E.C. Keystone, D.E. Furst, L.W. Moreland, M.H. Weisman, C.A. Birbara, et al.
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.
Arthritis Rheum, 48 (2003), pp. 35-45
[267.]
E. Keystone, B. Haraoui.
Adalimumab therapy in rheumatoid arthritis.
Rheum Dis Clin North Am, 30 (2004), pp. 349-364
[269.]
M.A. Fonder, D.L. Cummins, B.D. Ehst, G.J. Anhalt, J.H. Meyerle.
Adalimumab therapy for recalcitrant pyoderma gangrenosum.
J Burns Wounds, 5 (2006), pp. 8
[270.]
M.P. Heffernan, M.J. Anadkat, D.I. Smith.
Adalimumab treatmnt for pyoderma gangrenosum.
Arch Dermatol, 143 (2007), pp. 306-308
[271.]
J.A. van Laar, T. Missotten, P.L. van Daele, A. Jamnitski, G.S. Baarsma, P.M. van Hagen.
Adalimumab: a new modality for Behçet's disease?.
Ann Rheum Dis, 66 (2007), pp. 565-566
[272.]
B. Mushtaq, T. Saeed, R.D. Situnayake, P.I. Murray.
Adalimumab for sight-threatening uveitis in Behçet's disease.
Eye, 21 (2007), pp. 824-825
[273.]
D.K. Moul, N.J. Korman.
The cutting edge. Severe hidradenitis suppurativa treated with adalimumab.
Arch Dermatol, 142 (2006), pp. 1110-1112
[274.]
N. Scheinfeld.
Treatment of coincident seronegative arthritis and hidradenitis suppurativa with adalimumab.
J Am Acad Dermatol, 55 (2006), pp. 163-164
[275.]
L. Thirion, D. Picard, O. Mejjad, P. Courville, X. Le Loet, P. Joly.
[Cutaneous vasculitis with necrotic ulcers in rheumatoid arthritis: treatment with anti-TNFalpha].
Ann Dermatol Venereol, 133 (2006), pp. 453-455
[276.]
M.M. Ahmed, E. Mubashir, S. Hayat, M. Fowler, S.M. Berney.
Treatment of refractory temporal arteritis with adalimumab.
Clin Rheumatol, 26 (2007), pp. 1353-1355
[277.]
F. Tato, J. Rieger, U. Hoffmann.
Refractory Takayasu's arteritis successfully treated with the human, monoclonal antitumor necrosis factor antibody adalimumab.
Int Angiol, 24 (2005), pp. 304-307
[278.]
M.A. Philips, J. Lynch, F.H. Azmi.
Ulcerative cutaneous sarcoidosis responding to adalimumab.
J Am Acad Dermatol, 53 (2005), pp. 917
[279.]
M.P. Heffernan, D.I. Smith.
Adalimumab for treatment of cutaneous sarcoidosis.
Arch Dermatol, 142 (2006), pp. 17-19
[280.]
J.L. Callejas-Rubio, N. Ortego-Centeno, L. López-Pérez, M.N. Benticuaga.
Treatment of therapy-resistant sarcoidosis with adalimumab.
Clin Rheumatol, 25 (2006), pp. 596-597
[281.]
G.H. Fisher, R.G. Geronemus.
Treatment of multiple familial trichoepitheliomas with a combination of aspirin and a neutralizing antibody to tumor necrosis factor alpha: A case report and hypothesis of mechanism.
Arch Dermatol, 142 (2006), pp. 782-783
[282.]
S.E. Shannon, H.R. Schumacher, S. Self, A.N. Brown.
Multicentric reticulohistiocytosis responding to tumor necrosis factor-alpha inhibition in a renal transplant patient.
J Rheumatol, 32 (2005), pp. 565-567
[283.]
S.M. Howell, G.T. Bessinger, C.E. Altman, C.M. Belnap.
Rapid response of IgA pemphigus of the subcorneal pustular dermatosis subtype to treatment with adalimumab and mycophenolate mofetil.
J Am Acad Dermatol, 53 (2005), pp. 541-543
Copyright © 2007. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
